Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 2/2017

01-04-2017 | Erratum

Erratum to: Zebrafish phenotypic screen identifies novel Notch antagonists

Authors: Vithya Velaithan, Kazuhide Shaun Okuda, Mei Fong Ng, Norazwana Samat, Sze Wei Leong, Siti Munirah Mohd Faudzi, Faridah Abas, Khozirah Shaari, Sok Ching Cheong, Pei Jean Tan, Vyomesh Patel

Published in: Investigational New Drugs | Issue 2/2017

Login to get access

Excerpt

Erratum to: Invest New Drugs 2017 …
Metadata
Title
Erratum to: Zebrafish phenotypic screen identifies novel Notch antagonists
Authors
Vithya Velaithan
Kazuhide Shaun Okuda
Mei Fong Ng
Norazwana Samat
Sze Wei Leong
Siti Munirah Mohd Faudzi
Faridah Abas
Khozirah Shaari
Sok Ching Cheong
Pei Jean Tan
Vyomesh Patel
Publication date
01-04-2017
Publisher
Springer US
Published in
Investigational New Drugs / Issue 2/2017
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-017-0437-0

Other articles of this Issue 2/2017

Investigational New Drugs 2/2017 Go to the issue

PRECLINICAL STUDIES

Zebrafish phenotypic screen identifies novel Notch antagonists

PHASE I STUDIES

Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors

SHORT REPORT

Safety of raltegravir-based antiretroviral therapy in HIV-infected patients receiving multi-kinase inhibitors

PHASE I STUDIES

A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone

PRECLINICAL STUDIES

Pharmacokinetics and derivation of an anticancer dosing regimen for the novel anti-cancer agent isobutyl-deoxynyboquinone (IB-DNQ), a NQO1 bioactivatable molecule, in the domestic felid species

PRECLINICAL STUDIES

Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits